AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04680286 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose, intravenous bolus. Administered as the experimental arm.
Study NCT02307019 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Program on specific prevention of health
Description: The intervention will be centered in provide effective tools to manage each situation presented while a caregiver cares for patients poststroke with upper limb apraxia. Moreover, the workshops will be focused on the balance between the assistance provided by the caregiver and the improvement and the increase the autonomy and independence of the patients. Finally, we will provide skills and strategies to the caregiver for enhancing the environment adaptation of the patients.
Study NCT02307019 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Program on general prevention of health
Description: The general health educative program will consist in an educational workshop for caregivers where they are taught the habitual guidelines to caring for patients in situation of dependency.
Study NCT03411213 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: diffuse optical tomography
Description: Optical tomography is a form of computed tomography that creates a digital volumetric model of an object by reconstructing images made from light transmitted and scattered through an object.
Study NCT01670513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-118 Low Strength
Description: 8 weeks
Study NCT01670513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-118 High Strength
Description: 8 weeks
Study NCT01474083 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose-matched placebo. Oral administration.
Study NCT00939640 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DASH/sodium-restricted diet (SRD)
Description: Baseline diet will be assessed via Block Food Frequency Questionnaire, and 24-hour urinary sodium, potassium, and 8-isoprostanes will be measured. Subjects will then be assigned to 21 days of the DASH/SRD, with all food and beverages provided. Adherence will be assessed through a three-day food diary at the midpoint of the intervention, and at the end of the study urinary sodium, potassium, and 8-isoprostanes will again be measured.
Study NCT04205981 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: 8-week aerobic exercise (moderate intensity), 5 times per week, 60 min per session. Exercise training under supervision of trained staff.
Study NCT00886561 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV risk reduction intervention
Description: Education intervention designed to reduce HIV risk behaviors and enhance HIV prevention behaviors among female sex workers in Armenia
Study NCT00886561 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV risk reduction intervention
Description: Education intervention designed to reduce HIV risk behaviors and enhance HIV prevention behaviors among female sex workers in Armenia
Study NCT03882112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIP1601 40mg
Description: Single dosing of HIP1601 40mg, orally
Study NCT03215264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxychloroquine
Description: 600-1200mg daily
Study NCT03215264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entinostat
Description: 3-5mg weekly
Study NCT02320435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: In general, patients will continue to receive 420 milligrams (mg) of pertuzumab administered as an intravenous infusion every 3 weeks following the guidance of the Parent protocol.
Study NCT02320435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: If trastuzumab intravenous infusions were given in combination with pertuzumab as part of the Parent study, patients will continue to receive treatment at the same dose, schedule and under the same administration guidelines which were in effect at the time of Parent study closure.
Study NCT03215264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regorafenib
Description: 160mg daily
Study NCT02320435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Other Combination Anti-Cancer Therapies
Description: If other anti-cancer therapies were given in combination with pertuzumab as part of the Parent study, patients will receive all treatments at the same dose, schedule and under the same administration guidelines which were in effect at the time of Parent study closure.
Study NCT02151006 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DHEA
Study NCT02471248 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankle Robot with Power Assistance
Description: Stroke patients will enrol in a 20-session gait training program for at least two sessions per week. In each session, the stroke patient will walk overground continuously for 2 \* 10 minutes and walk up/down a staircase (about 10 steps per flight) for 10 minutes, rest will be provided in between each round of walking or stair climbing. This training can promote gait recovery and physical fitness.~They will wear the Ankle Robot during the gait training. The motor will synchronise with the paretic-side gait pattern to provide dorsiflexion moment during swing phase, and free the ankle joint when the sole is loaded.
Study NCT02471248 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham
Description: Stroke patients will enrol in a 20-session gait training program for at least two sessions per week. In each session, the stroke patient will walk overground continuously for 2 \* 10 minutes and walk up/down a staircase (about 10 steps per flight) for 10 minutes, rest will be provided in between each round of walking or stair climbing. This training can promote physical fitness.~They will wear the Ankle Robot during the gait training. The robot will synchronise with the paretic-side gait pattern to the Ankle Robot provides very low assistance which can be barely perceived by the stroke patient but does not suffice to support the ankle dorsiflexion.
Study NCT00166010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nesiritide
Description: Standard dose of nesiritide which is a loading dose of 1 mcg/kg IV over 30 minutes followed by a nesiritide infusion at 0.01mcg/kg/min. All patients will be continually evaluated. At any time the attending physician may add or adjust treatment if deemed clinically indicated.
Study NCT01513096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: itopride
Description: itopride, 10mg, twice per day, for 1 day
Study NCT02296073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: midazolam 3～5μg/kg•min for maintenance of sedation.
Study NCT02296073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine 0.5μg/kg intravenous bump for 15 min，then 0.2～1.4μg/(kg.h) for maintenance of sedation；
Study NCT02296073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine 0.25μg/kg intravenous bump for 15 min，then 0.2～1.4μg/(kg.h) for maintenance of sedation；
Study NCT05111496 — intervention group
Intervention type: RADIATION
Intervention: Gafchromic film
Description: Before the X-ray radiation, a Gafchromic film will be placed on the patient's back at the start of the operation
Study NCT00387387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Pazopanib is an oral inhibitor of vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and c-kit kinases
Study NCT00387387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX 6
Description: FOLFOX 6 treatment consists of intravenous (IV) oxaliplatin (100 milligram per meter\^2\[mg/m\^2\]), and folinic acid (400 mg/m\^2), IV 5-fluorouracil bolus (400 mg/m\^2) followed by IV 5-fluorouracil (2400 to 3000 mg/m\^2) infusion over 48 hours on Day 1 of every 14-day cycle.
Study NCT00387387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CapeOx
Description: CapeOx treatment consists of IV oxaliplatin (130 mg/m\^2) on Day 1 plus oral capecitabine (1000 mg/m\^2) twice daily on Days 2 through 14 of every 21-day cycle. Reduced CapeOx treatment will be administered according to the same schedule as the CapeOx treatment, but the dose of capecitabine will be reduced to 850 mg/m\^2 twice daily.
Study NCT02296073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine 0.2～1.4μg/(kg.h) for maintenance of sedation；
Study NCT03311607 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: AmBisome
Description: A total dose of 15 mg/kg AmBisome given in doses of 3 mg/kg in a biweekly dosing schedule
Study NCT00773760 — intervention group
Intervention type: OTHER
Intervention: SNP genotyping
Description: Coded blood specimens will be transported to the Department of Gene Technology TTÜ and genotyping analysis will be performed. Lymphocytes will be isolated from blood specimens using Ficol-Paq gradients, and genomic DNA isolated using a salting-out procedure. Variants of the MOR gene and other genes of interests will be performed by DNA sequence analysis of PCR-amplified DNA, using primers located in flanking intron sequence. All methods proposed are currently in operation in the respective facilities.
Study NCT04204915 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aortic valve replacement
Description: Participants will be assessed by a member of the surgical team performing aortic valve replacement (AVR), and by any other relevant medical professionals identified by the doctors overseeing their care in hospital. When deemed ready for AVR, a member of the surgical team will ask for consent to proceed with the AVR. They will discuss the surgical procedure, covering information on the basic technical procedure, risks and expected recovery time.
Study NCT02099916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gonadotropins plus DHEA
Description: Women in the DHEA group will received 25 mg of DHEA three times a day for at least 12 weeks.
Study NCT02099916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonadotropins
Description: All patients will be stimulated with a fixed GnRH-antagonist protocol. Ovarian stimulation will be initiated with 450 IU of gonadotropins either in the form of a combination of highly purified urinary FSH and LH or with a combination of Rec FSH and Rec LH.
Study NCT03271151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cymbalta
Description: Duloxetine (Cymbalta) is a serotonin and norepinephrine dual reuptake inhibitor (SNRI) that is an effective treatment for painful diabetic neuropathy. It is approved for major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathy, fibromyalgia, and chronic musculoskeletal pain
Study NCT03271151 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to compare outcomes against Duloxetine
Study NCT02296073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl 0.5～4 μg/(kg.h) for maintenance of analgesia
Study NCT02296073 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: assessment
Description: Ramsay score for sedation assessment, Facial expression, leg movement, activity, cry, and consolability score (FLACC) for analgesia assessment.
Study NCT04977557 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Thiamine
Description: Injection Thiamine 200 mg daily intravenously for 1 week followed by Tablet Thiamine 100mg bid for remaining 11 weeks
Study NCT02954250 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Cognitive Therapy
Description: The 8-week MMBCT protocol combines the practice of specific meditation techniques with cognitive therapy principles applicable to anxiety and depression. Each session will cover a meditation practice, as well as a relevant topic for discussion. The initial sessions will introduce general concepts of mindfulness (non-judgemental awareness, being in the moment, fostering curiosity, etc.), which will be expanded to more elaborate notions that are particularly relevant to anxiety, depression and suicidal ideations (recognizing thoughts are not facts, cultivating loving kindness for oneself, improving communication with others, etc.) Participants will be encouraged to practice the mindfulness techniques between sessions, a process that will be reviewed during groups in an ongoing fashion.
Study NCT01716390 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Drink that contains plant stanols
Study NCT01716390 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Study NCT03980977 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: skin biopsy
Description: skin biopsy will be taken under local anesthesia using a patch of lidocaine and prilocaine. In practice, during the skin biopsy, the skin must be cleaned with chlorhexidine or alcohol, to the exclusion of any other antiseptic. The biopsy will preferably be done with a dermatome (or punch, 12 G).
Study NCT02118506 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical practice
Description: The control group underwent familiarization of gait phases using cards with gait phases and physical gait training.~Familiarization with gait cycle: Cards with pictures of an elderly person performing movements related to the adjustment of posture, gait initiation and gait phases were shown to the subjects. They should have organized them sequentially, showing that they learned gait phases. Then, they were submitted to a physical gait training. They underwent a single training session during 1 hour and 30 minutes and were reassessed 10 minutes and 1 day after the end of the session, in respect of the kinematic gait and mobility.
Study NCT02118506 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental and physical practice
Description: The experimental group underwent familiarization of gait phases using cards with gait phases, mental practice of gait and physical gait training.~Familiarization with gait cycle: Cards with pictures of an elderly person performing movements related to the adjustment of posture, gait initiation and gait phases were shown to the subjects. They should have organized them sequentially, showing that they learned gait phases.~Then, they were submitted to a mental training of gait. They imagined the gait steps per 400 repetitions. While imagining, they verbalized the gait phases.~Finally, they were submitted to a physical gait training. They executed 400 steps.~They underwent a single training session during 1 hour and 30 minutes and were reassessed 10 minutes and 1 day after the end of the session, in respect of the kinematic gait and mobility.
Study NCT04087044 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Computerized Rotational Head Impulse Test ( crHIT)-Vertical
Description: 1. Oculo-Motility and Positional Testing,~2. Caloric Testing
Study NCT04087044 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computerized Rotational Head Impulse Test ( crHIT)-Vertical
Description: 1. Oculo-Motility and Positional Testing,~2. Caloric Testing
Study NCT00630513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertapenem
Description: 3 days regimen with Ertapenem (1 g/day i.v.)
Study NCT00630513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ampicillin-Sulbactam
Description: 3 days treatment with Ampicillin-Sulbactam (AS 3g x 3/ day i.v.)
Study NCT02209987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-5745 SC
Description: GS-5745 150 mg administered by SC injection formulated as a sterile, aqueous buffered solution in a single-use pre-filled syringe
Study NCT02209987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-5745 IV
Description: GS-5745 150 mg administered by IV infusion formulated as a sterile, aqueous buffered solution in single-use glass vials
Study NCT02960932 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound scanner
Description: Ultrasound scanner used to the SSI technical reproducibility.
Study NCT02421328 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP first (Fisher & Paykel Healthcare)
Description: Infants will start on nasal CPAP for 60 minutes and then switched to HHHFNC for anther 60 minutes. Ultrasonographic assessment of diaphragmatic dimensions and excursion will be done at the end of each 60 minute epochs.
Study NCT02421328 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HHHFNC first (Fisher & Paykel Healthcare)
Description: Infants will start on HHHFNC for 60 minutes and then switched to nasal CPAP for anther 60 minutes. Ultrasonographic assessment of diaphragmatic dimensions and excursion will be done at the end of each 60 minute epochs.
Study NCT03484923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: 400 mg of PDR001 administered every 4 weeks intravenously
Study NCT01691911 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote preconditioning
Description: Immediately after induction of anaesthesia, a standard, CE-approved tourniquet cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure >185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 4 ischaemia-reperfusion cycles. In all other respects, the procedure and peri-operative care will follow the routine practices of the surgeons and anaesthetists involved.
Study NCT04252664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: RDV 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.
Study NCT04252664 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Remdesivir placebo
Description: RDV placebo 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.
Study NCT02371889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: Max therapeutic dose of 200mg/day
Study NCT02371889 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Medical Management
Description: Medical Management (MM; Pettinati, 2004) will support subjects' efforts to reduce or stop their drinking. The study nurse makes direct recommendations for reducing drinking to sensible levels. The first session will use the brochure A Guide to Sensible Drinking (WHO 1996). The subject is provided with information about pharmacotherapy and the importance of adherence to topiramate/placebo. Subsequent treatment sessions (15-25 minutes) will be conducted at each study visit, during which the nurse will perform an assessment of the subject's drinking, monitor his/her medication adherence, and make recommendations to follow until the next visit. Men will be advised to consume no more than 3 drinks 4 times per week; women will be advised to consume no more than 2 drinks 4 times per week.
Study NCT02371889 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medical Management
Description: Medical Management (MM; Pettinati, 2004) will support subjects' efforts to reduce or stop their drinking. The study nurse makes direct recommendations for reducing drinking to sensible levels. The first session will use the brochure A Guide to Sensible Drinking (WHO 1996). The subject is provided with information about pharmacotherapy and the importance of adherence to topiramate/placebo. Subsequent treatment sessions (15-25 minutes) will be conducted at each study visit, during which the nurse will perform an assessment of the subject's drinking, monitor his/her medication adherence, and make recommendations to follow until the next visit. Men will be advised to consume no more than 3 drinks 4 times per week; women will be advised to consume no more than 2 drinks 4 times per week.
Study NCT02371889 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inactive Placebo
Description: In capsules indistinguishable from topiramate capsules and gradually increased to a maximum equivalent of 200 mg of topiramate/day
Study NCT03980977 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: tumor biopsy
Description: an additional tumor sample will be taken during programmed diagnostic procedure.
Study NCT03980977 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: blood sample
Description: blood sample will be taken for biological collection
Study NCT03208127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment with Direct Acting Antiviral tablet
Description: HCV Treatment for 12 Weeks
Study NCT01254214 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: tMBSR
Description: MBSR is an 8-week program of mindfulness meditation and gentle Hatha yoga, taught in a class of up to 30 participants. The telephone-adapted MBSR program (tMBSR) begins with a 5 hour-day workshop to introduce the techniques, followed by 6 weekly 1 ½ hour group teleconferences with the teacher to discuss the class's experiences with meditation practice, and ends with a 5 hour retreat in week 8.
Study NCT01254214 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Support group
Description: The attention control consists of a support group emphasizing communication skills and selecting resources. It includes two 90 minute in-person workshops and 6 1-hour teleconference calls. An experienced facilitator emphasizes communication skills and group support.
Study NCT00961649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension